Cord Dohrmann
Chief Tech/Sci/R&D Officer at EVOTEC SE
Net worth: 3 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mario Polywka | M | 61 | 20 years | |
| Iris Löw-Friedrich | M | 63 | 10 years | |
| Laetitia Rouxel | F | 51 | 1 years | |
| Craig Johnstone | M | 54 | 12 years | |
| Marco J. Janezic | M | - |
Eternygen GmbH
 Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | 12 years |
| Gabriele Hansen | F | - | - | |
| Kees van der Graaf | M | 73 |
FSHD Unlimited Cooperatie Ua
 FSHD Unlimited Cooperatie Ua Pharmaceuticals: MajorHealth Technology FSHD Unlimited Cooperatie Ua is a Dutch pharmaceutical company that specializes in facioscapulohumeral dystrophy. The private company is based in Leiden, the Netherlands and has subsidiaries in the Netherlands. The company was founded by Cornelis van der Graaf. | 10 years |
| John Pohlner | M | - |
Evotec International GmbH
 Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. | 30 years |
| Jonathan Edwards | M | 40 |
Breakpoint Therapeutics GmbH
 Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | - |
| Hinnerk Rohwedder | M | - | 3 years | |
| Matthias Evers | M | 51 | 2 years | |
| Constanze Ulmer-Eilfort | M | 62 | 3 years | |
| Jonathan Hollick | M | - |
Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | 5 years |
| Daniel Speidel | M | - |
Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | 5 years |
| Camilla Languille | F | 41 | 2 years | |
| Michael J. McKenna | M | 67 |
Harvard Medical School
| 28 years |
| Elaine Sullivan | M | 63 | 9 years | |
| Peter Finan | M | 57 |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | - |
| James J. Mongan | M | 82 |
Harvard Medical School
| 28 years |
| Grit Zahn | M | - |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | 11 years |
| John Halamka | M | 61 |
Harvard Medical School
| 28 years |
| Roland Sackers | M | 56 | 5 years | |
| Juan Jaen | M | 66 |
Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | - |
| Jean-Pierre Kinet | M | 70 |
Harvard Medical School
| 29 years |
| Volker Braun | M | - | - | |
| Klaus Schollmeier | M | 67 |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | - |
| Richard Mulligan | M | 69 |
Harvard Medical School
| 28 years |
| Allan Mackay | M | 68 |
Facio Therapies
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Werner Lanthaler | M | 56 |
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | 15 years |
| Claus Tycho Bræstrup | M | 79 | - | |
| Paul Herrling | M | 78 | 3 years | |
| Arne Johannes Reif | M | 69 |
Eberhard Karls Universität Tübingen
| 12 years |
| Colin Bond | M | 64 |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | 6 years |
| Wolfgang Plischke | M | 72 | 7 years | |
| Bernd Hirsch | M | 53 | - | |
| Carsten Dehning | M | - |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | 12 years |
| Walter Wenninger | M | 86 | 6 years | |
| Mary C. Tanner | F | 73 | 9 years | |
| Martin Wansleben | M | 65 |
Eberhard Karls Universität Tübingen
| 2 years |
| Vladimir Torchilin | M | 77 |
Harvard Medical School
| 4 years |
| Reiner Strecker | M | 63 |
Eberhard Karls Universität Tübingen
| 4 years |
| Annabel Chen-Tournoux | M | - |
Harvard Medical School
| 4 years |
| Andreas Pinkwart | M | 64 | 3 years | |
| Elizabeth Garner | M | 56 |
Harvard Medical School
| 3 years |
| A. Sorensen | M | 62 |
Harvard Medical School
| 16 years |
| Roland Wehr | M | - |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | 8 years |
| Hugo Hämmerle | M | 72 |
Eberhard Karls Universität Tübingen
| 3 years |
| Robert Siegle | M | 56 |
Eberhard Karls Universität Tübingen
| 3 years |
| Michael Shalmi | M | 59 | - | |
| Roland Weiger | M | 63 |
Eberhard Karls Universität Tübingen
| 4 years |
| Lian Shan Zhang | M | 63 |
Eberhard Karls Universität Tübingen
| 6 years |
| Peter Bremme | M | 64 |
Eberhard Karls Universität Tübingen
| 1 years |
| Vamsi Mootha | M | - |
Harvard Medical School
| 3 years |
| Richard P. Lifton | M | 71 |
Harvard Medical School
| 2 years |
| Christoph Schubert | M | 63 |
Eberhard Karls Universität Tübingen
| 3 years |
| William Hahn | M | - |
Harvard Medical School
| 3 years |
| Monika Conradt | F | - | - | |
| Iris Epple-Righi | F | 58 |
Eberhard Karls Universität Tübingen
| 4 years |
| Christoph Burkhard | M | 60 |
Eberhard Karls Universität Tübingen
| 4 years |
| Colleen Delaney | M | 57 |
Harvard Medical School
| 3 years |
| Phillip Schwartz | M | 61 |
Harvard Medical School
| 3 years |
| Li-Huei Tsai | M | 64 |
Harvard Medical School
| 12 years |
| David Tancredi | M | - |
Harvard Medical School
| 7 years |
| Susan Mistler | M | - |
Harvard Medical School
| 1 years |
| Leesa Gentry | F | 54 | 13 years | |
| Gregor Hagedorn | M | - |
Eberhard Karls Universität Tübingen
| 7 years |
| Manfred W. Schmolz | M | - |
Eberhard Karls Universität Tübingen
| 3 years |
| Boris Bergus | M | 59 |
Harvard Medical School
| 3 years |
| Thomas Nautsch | M | 67 |
Eberhard Karls Universität Tübingen
| 4 years |
| Cecilia Gonzalo | F | 49 |
Harvard Medical School
| 1 years |
| H. Naqvi | M | 59 |
Harvard Medical School
| 3 years |
| Michael M. Wick | M | 77 |
Harvard Medical School
| 13 years |
| Roland Oetker | M | 75 | 3 years | |
| Helmut Schühsler | M | 65 |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | - |
| Alexander Arrow | M | 53 |
Harvard Medical School
| 3 years |
| Marc Fogassa | M | 57 |
Harvard Medical School
| 3 years |
| Denise Scots-Knight | M | 64 |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | - |
| Peter John Fellner | M | 80 | 6 years | |
| Manfred Rüdiger | M | 59 |
Eberhard Karls Universität Tübingen
| 6 years |
| Guenther Karmann | M | - |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | 4 years |
| Alwin Epple | M | 61 |
Eberhard Karls Universität Tübingen
| 4 years |
| Andreas Hermann Renschler | M | 65 |
Eberhard Karls Universität Tübingen
| 3 years |
| Stefan Zoller | M | 66 |
Eberhard Karls Universität Tübingen
| 3 years |
| Wolfgang Mutter | M | - |
Eberhard Karls Universität Tübingen
| 3 years |
| Rainer Kirchdörfer | M | 66 |
Eberhard Karls Universität Tübingen
| 5 years |
| Kathrin Shem-Tov | F | - |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | - |
| Brett Zbar | M | 51 |
Harvard Medical School
| 4 years |
| Enno Spillner | M | 55 | 7 years | |
| Jeffrey Kang | M | - |
Harvard Medical School
| 10 years |
| Bernhard Nick | M | 66 |
Eberhard Karls Universität Tübingen
| 3 years |
| Theodor Weimer | M | 65 |
Eberhard Karls Universität Tübingen
| 6 years |
| R. Alan B. Ezekowitz | M | 70 |
Harvard Medical School
| 10 years |
| Philip A. Pizzo | M | 79 |
Harvard Medical School
| 10 years |
| Mark Goldberg | M | 69 |
Harvard Medical School
| 22 years |
| Hubertine Underberg-Ruder | M | 62 |
Eberhard Karls Universität Tübingen
| 4 years |
| Junying Yuan | M | - |
Harvard Medical School
| - |
| Matthias Stuber | M | - |
Harvard Medical School
| 6 years |
| William A. Haseltine | M | 79 |
Harvard Medical School
| 17 years |
| Kasim Kutay | M | 59 | - | |
| Kenneth Tsai | M | - |
Harvard Medical School
| 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 66 | 66.00% |
| United States | 32 | 32.00% |
| Netherlands | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cord Dohrmann
- Personal Network
